Corpay Cross-Border成為皇家馬德里俱樂部官方合作夥伴
多倫多--(BUSINESS WIRE)--(美國商業資訊)-- 企業支付領域的全球領導者Corpay, Inc.* (NYSE: CPAY)欣然宣布，Corpay的Cross-Border業務部門已與皇家馬德里俱樂部達成協議，成為其官方合作夥伴。
透過此次合作，皇家馬德里將能夠獲得並使用Corpay Cross Border的創新解決方案，以協助緩解其日常業務需求帶來的外匯風險。
Corpay Cross-Border Solutions行銷長Brad Loder表示：「Corpay Cross-Border團隊很榮幸能成為皇家馬德里的官方合作夥伴——這是全球知名度最高、粉絲最多的運動品牌之一。我們正大力發展Corpay品牌及貨幣風險管理業務，能與全球最成功的足球俱樂部之一合作，讓我們倍感振奮。」
關於Corpay
Corpay, Inc. (NYSE: CPAY)是一家全球性標準普爾500指數企業支付公司，致力於協助企業和消費者以簡單、可控的方式支付費用。Corpay的現代支付解決方案套件可協助客戶更好地管理與車輛相關的費用（如加油和停車）、旅行費用（如酒店預訂）和應付帳款（如向供應商付款），從而為客戶節省時間並最終降低支出。Corpay Cross-Border是指由Corpay, Inc.擁有和經營的一組法律實體。
Corpay – 讓付款變得簡單。如欲瞭解更多資訊，請造訪 www.corpay.com 。
關於皇家馬德里俱樂部
皇家馬德里俱樂部是一家擁有123年歷史的運動實體。它是獲得歐洲足球聯賽冠軍（15次）和歐洲籃球聯賽冠軍（11次）次數最多的俱樂部，並被國際足球總會評選為二十世紀最佳俱樂部。皇家馬德里在全球擁有大量球迷，社群媒體粉絲超過6.2億，根據Brand Finance的資料，皇家馬德里連續三年蟬聯全球最強足球品牌，也是2023-24賽季全球收入最高的足球俱樂部（Deloitte足球俱樂部財富榜）。如欲瞭解有關皇家馬德里俱樂部的更多資訊，請造訪連續七年造訪量最大的足球俱樂部網站： www.realmadrid.com 。
*本文件中的「Corpay」主要指Corpay, Inc.的Cross-Border業務部門（網址： https://www.corpay.com/cross-border ）；Corpay Cross-Border旗下公司的完整列表請參見此處： https://www.corpay.com/compliance 。
** 須獲得相關Corpay公司的信用與合規核准。
免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate. One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451. There were no TEAEs related to LFTs in SION-719-treated subjects. The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state. SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily. Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators. Next Steps For SION-719: Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients. Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label. The study will be completed before the Phase 2a trial is initiated. Next Steps For SION-451: Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109. The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients. Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026. In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with approximately $219.2 million in gross proceeds. Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday. Read Next:Photo by Gorodenkoff via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
15 minutes ago
- Yahoo
Sprinklr (CXM) Stock Trades Up, Here Is Why
Shares of customer experience software provider Sprinklr (NYSE:CXM) jumped 5.7% in the morning session after the company reported a "beat-and-raise" quarter (Q1 FY-26). Sprinklr raised its full-year revenue and EPS guidance, which blew past analysts' expectations. The quarter was also solid as its revenue, EPS, and adjusted operating income exceeded Wall Street's estimates. The big win came on margins. Operating margin on a non-GAAP basis climbed to 18% from 11% last year, helped by pulling back on sales and marketing costs. That made a real difference in earnings per share, which jumped more than 30% and blew past Wall Street's estimates. Overall, we think this was a solid "beat-and-raise" quarter. After the initial pop the shares cooled down to $8.75, up 2.2% from previous close. Is now the time to buy Sprinklr? Access our full analysis report here, it's free. Sprinklr's shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 12 months ago when the stock dropped 24.2% on the news that the company reported weak first quarter results and provided full-year revenue guidance below expectations after being lowered. Also, its revenue guidance for next quarter missed Wall Street's estimates. The company called out a soft demand environment with longer sales cycles and heightened budgetary scrutiny. In addition, it observed higher churn in its core product suites due to reduced marketing spend, elimination of programs, and seat reductions. These issues contributed to the weak guidance as management expects the elevated churn level to continue for the full year FY '25. On the other hand, Sprinklr recorded significant improvement in new large contract wins. Overall, the guidance was quite bad and weighed on the stock. Following the results, D.A. Davidson downgraded the stock's rating from Buy to Neutral, while Cantor Fitzgerald also lowered the rating from Overweight to Neutral. Sprinklr is up 2.4% since the beginning of the year, but at $8.75 per share, it is still trading 19.3% below its 52-week high of $10.84 from June 2024. Investors who bought $1,000 worth of Sprinklr's shares at the IPO in June 2021 would now be looking at an investment worth $496.87. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
26 minutes ago
- Yahoo
Nearly 300 employees out of work after Johnsonville closes packing plant in far south suburbs
MOMENCE, Ill. — A packing plant in the far south suburbs has closed, putting nearly 300 employees out of work. The Momence Packing Company, located at 334 North Street in Momence, was shuttered as of Monday, a spokesperson for Johnsonville, the Wisconsin-based sausage manufacturer, has confirmed. Ground beef sold nationwide possibly contaminated with E. coli The Momence facility was built in 1962 and began producing Johnsonville products in 1995. According to Johnsonville, the closing impacts 274 employees, who were notified Monday and will receive continued pay and benefits for 60 days. 'We made the difficult decision after evaluating how best to optimize our operations network to address current and future growth,' the spokesperson said in a statement. 'The work from this facility will transition to three other production facilities in Wisconsin and Kansas.' Read more: Latest Chicago news and headlines Johnsonville said it plans to demolish the Momence facility by the end of this year. The company also says about 100 new jobs will be created between two of its Wisconsin plants by the third quarter of this year, 20 to 25 new jobs in Sheboygan Falls and 70 to 75 new jobs in Watertown. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
